Cost effectiveness of screening for Chlamydia trachomatis in Ireland

In our analysis we estimated the cost and cost-effectiveness of opportunistic screening for Chlamydia trachomatis in Ireland, based on data from a pilot study. We found that a national screening programme would be expensive to implement nationally and would not be deemed cost-effective by policy makers in Ireland.

Journal ArticleGillespie P, O’Neill C, Adams E, et al. Cost effectiveness of opportunistic screening for Chlamydia trachomatis in Ireland. Sex Transm Infect 2012; 88:3, 222-228. doi:10.1136/sextrans-2011-050067

 

Read Publication

Costs and cost-effectiveness of different strategies for chlamydia screening and partner notification

Comparing cost effectiveness and sex equity of different intervention strategies within the English National Chlamydia Screening Programme found that increasing the effectiveness of partner notification was more cost effective and increased the diagnoses in women compared to increasing screening in men. The tool developed in this study can be used with local data to calculate cost effectiveness for chlamydia control programmes.

publication_iconTurner KME, Adams EJ, Grant A, et al. Costs and cost effectiveness of different strategies for chlamydia screening and partner notification: an economic and mathematical modelling study. BMJ, 4;342:c7250, 2011. 10.1136/bmj.c7250.

 

Read Publication

What is the cost of pelvic inflammatory disease and how much could be prevented by screening for chlamydia?

Data from a study of the incidence of pelvic inflammatory disease (PID) and healthcare behaviour were used to estimate the cost of managing PID and the potential impact of chlamydia screening. We found that the average cost of managing PID was £163 in community and hospital settings, and that over £60,000 could be saved in London alone from screening for chlamydia.

publication_iconAghaizu A, Adams EJ, Turner KME, et al. What is the cost of pelvic inflammatory disease and how much could be prevented by screening for Chlamydia trachomatis? Cost analysis of the POPI (prevention of pelvic infection) trial. Sex Transm Infect 2011; 87:312-317.

Read Publication